58827-18-2

Upstream product

• 614-99-3 Ethyl 2-furoate 
• 107-15-3 ethylenediamine 
• 527-69-5 2-furancarbonyl chloride 
• 57260-73-8 N-BOC-1,2-diaminoethane 

Downstream Products

• 58827-43-3 Furan-2-carboxylic acid {2-[2-hydroxy-3-(2-iodo-phenoxy)-propylamino]-ethyl}-amide 
• 58827-19-3 Furan-2-carboxylic acid [2-(2-hydroxy-3-phenoxy-propylamino)-ethyl]-amide 
• 58828-04-9 3-<<2-(2-furamido)ethyl>amino>-1-<2-(benzyloxy)phenoxy>propan-2-ol 
• 1311720-53-2 C₁₆H₁₉N₃O₃ 
• 83165-44-0 3-{[2-(2-tetrahydrofuramido)ethyl]amino}-1-(2-hydroxyphenoxy)propan-2-ol 
• 58827-33-1 Furan-2-carboxylic acid {2-[3-(2-allyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-amide 
• 58827-27-3 Furan-2-carboxylic acid [2-(2-hydroxy-3-o-tolyloxy-propylamino)-ethyl]-amide 

Relevant academic research and scientific papers

DIPEPTIDYL PEPTIDASE IV INHIBITOR

A compound represented by general formula (I):A-B-D whereinA represents a substituted or unsubstituted 1-pyrrolidinyl group, a substituted or unsubstituted 3-thiazolidinyl group, a substituted or unsubstituted 1-oxo-3-thiazolidinyl group, or the like;B r

α1-Adrenoceptor blocking activity of some ring-open analogues of prazosin

Synthesis and structural characterization of some ring-open analogues of Prazosin containing either the guanidine substructure or urea-equivalent groups are described. The opening of the pyrimidine ring in Prazosin is very important as far as the affinity for α1-adrenoceptor is concerned. The pA2 values of the ring-open derivatives are 104-105 fold lower than that of the parent. It is probable that the affinity decrease principally reflects a negative influence of the conformational factors in the interaction with the α1-receptor. The derivative 5 containing the guanidine moiety, charged at physiological pH, is as active as the other derivatives containing the uncharged urea-equivalent groups. This behaviour indicates, in this class of compounds, the importance of H-bonding interactions with the receptor. When in the ring-open models the ethanediamino substructure is substituted for the piperazine ring additional decrease in activity occurs.

β-Adrenergic blocking agents. 24. Heterocyclic substituted 1-(aryloxy)-3-[[(amido)alkyl]amino]propan-2-ols

The synthesis of a series of 1-(aryloxy)-3-[[(amido)alkyl]amino]propan-2-ols where either the aryl moiety is heterocyclic or the amidic group is substituted by a heterocyclic moiety is described. Several of the compounds were more potent that propranolol